Hypoplastic acute myelogenous leukaemia.
The clinical course, diagnosis and management of nine cases of hypoplastic acute myelogenous leukaemia are described. Such cases may follow a slowly progressive course and should not receive anti-leukaemic chemotherapy unless the disease is advancing rapidly or unless some specific complication develops. If chemotherapy has to be given, usually because of severe and recurrent infections, then prompt and prolonged remission of disease may occur.
D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous
D003561:Cytarabine; D003630:Daunorubicin